RLY-2608 + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
PIK3CA-Related Overgrowth Spectrum (PROS)
Conditions
PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations, Vascular Malformations, PIK3CA Mutation, CLOVES Syndrome, Klippel Trenaunay Syndrome, Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)
Trial Timeline
Jun 13, 2025 → Oct 1, 2031
NCT ID
NCT06789913About RLY-2608 + Placebo
RLY-2608 + Placebo is a phase 2 stage product being developed by Relay Therapeutics for PIK3CA-Related Overgrowth Spectrum (PROS). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06789913. Target conditions include PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations, Vascular Malformations.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06789913 | Phase 2 | Recruiting |
Competing Products
6 competing products in PIK3CA-Related Overgrowth Spectrum (PROS)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Miransertib | Merck | Phase 2 | 52 |
| Miransertib | Merck | Phase 1/2 | 41 |
| Alpelisib | Novartis | Phase 2 | 52 |
| Alpelisib | Novartis | Phase 2 | 52 |
| Alpelisib + Placebo | Novartis | Phase 2 | 52 |
| alpelisib | Novartis | Pre-clinical | 23 |